Company
Remedium Bio
Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs.
Also known as REMEDIUM BIO INC.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Boston, MA, United States
- Legal name
- REMEDIUM BIO INC.
- remedium-bio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Record updated 28 September 2026
About
Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy. The system has an exceptionally high degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost. Remedium's pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.
Funding snapshot
- Total raised
- $10MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A, $10M2026-08-10
Funding rounds
- Series A
- $10M2026-08-10, Company stated
- Round, 2026
- $1.5M2026-05-06, SEC form D sold, 1 investor
- Round, 2021
- $4.4M2021-11-05, SEC form D sold, 26 investors
About the company
- Status notes
- Remedium is a Boston based pre-clinical stage Biotechnology company driven by a single basic principle - we believe that any disease can be cured.
Products
- Other
- Prometheus adjustable gene therapy platform